MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as firstline therapy for RAS and BRAF wildtype metastatic colorectal cancer: A study by the Australasian Gastrointestinal Trials Group (AGITG)

Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for over a decade. The evidence for a “lighter” treatment approach is limited to mono-chemotherapy plus bevacizumab in the RAS unselected population. Anti-EGFR antibodies have activity as monotherapy or in combination with chemotherapy in RAS wildtype metastatic colorectal cancer.